Travere Therapeutics (TVTX) Competitors $19.68 -0.69 (-3.39%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$19.68 0.00 (0.00%) As of 03/28/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. SRPT, RVMD, BBIO, LNTH, TGTX, LEGN, AXSM, TLX, BPMC, and KRYSShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Sarepta Therapeutics Revolution Medicines BridgeBio Pharma Lantheus TG Therapeutics Legend Biotech Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Krystal Biotech Travere Therapeutics (NASDAQ:TVTX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Do institutionals and insiders hold more shares of TVTX or SRPT? 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by company insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is TVTX or SRPT more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Travere Therapeutics' net margin of -137.90%. Sarepta Therapeutics' return on equity of 11.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-137.90% -1,636.87% -55.95% Sarepta Therapeutics 7.43%11.00%3.35% Does the MarketBeat Community believe in TVTX or SRPT? Sarepta Therapeutics received 1383 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 75.09% of users gave Sarepta Therapeutics an outperform vote while only 59.44% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes8559.44% Underperform Votes5840.56% Sarepta TherapeuticsOutperform Votes146875.09% Underperform Votes48724.91% Which has more risk & volatility, TVTX or SRPT? Travere Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Do analysts rate TVTX or SRPT? Travere Therapeutics presently has a consensus price target of $30.62, indicating a potential upside of 55.57%. Sarepta Therapeutics has a consensus price target of $167.41, indicating a potential upside of 137.76%. Given Sarepta Therapeutics' higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Sarepta Therapeutics 1 Sell rating(s) 3 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has better valuation & earnings, TVTX or SRPT? Travere Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$233.18M7.49-$111.40M-$4.10-4.80Sarepta Therapeutics$1.90B3.59-$535.98M$2.2830.88 Does the media refer more to TVTX or SRPT? In the previous week, Sarepta Therapeutics had 5 more articles in the media than Travere Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 8 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.60 beat Sarepta Therapeutics' score of 0.46 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sarepta Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral SummarySarepta Therapeutics beats Travere Therapeutics on 15 of the 19 factors compared between the two stocks. Remove Ads Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.75B$6.90B$5.63B$7.83BDividend YieldN/A2.74%4.57%4.01%P/E Ratio-4.807.1723.3318.67Price / Sales7.49220.47388.3491.01Price / CashN/A65.6738.1634.64Price / Book7.376.396.894.23Net Income-$111.40M$142.12M$3.20B$247.15M7 Day Performance-4.14%-5.06%-2.98%-2.17%1 Month Performance-8.04%-7.49%1.63%-5.68%1 Year Performance155.25%-10.91%9.44%-0.74% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.7709 of 5 stars$19.68-3.4%$30.62+55.6%+155.3%$1.75B$233.18M-4.80460News CoveragePositive NewsSRPTSarepta Therapeutics4.8256 of 5 stars$76.33+3.0%$167.41+119.3%-45.6%$7.41B$1.90B61.061,314RVMDRevolution Medicines4.1315 of 5 stars$39.34+3.2%$66.31+68.6%+15.9%$7.31B$742,000.00-10.96250Positive NewsBBIOBridgeBio Pharma4.5948 of 5 stars$37.22+7.0%$52.90+42.1%+13.6%$7.08B$221.90M-13.06400Insider TradeHigh Trading VolumeLNTHLantheus4.2597 of 5 stars$99.44+1.8%$129.43+30.2%+54.5%$6.81B$1.53B16.55700TGTXTG Therapeutics3.0428 of 5 stars$42.61-0.9%$40.67-4.6%+162.1%$6.69B$329.00M-426.06290Positive NewsLEGNLegend Biotech2.8557 of 5 stars$36.33-1.7%$79.00+117.5%-37.5%$6.67B$627.24M-38.241,800Short Interest ↓Positive NewsAXSMAxsome Therapeutics4.7455 of 5 stars$129.17+1.9%$167.36+29.6%+48.5%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.24+2.5%$22.00+20.6%N/A$6.14B$783.21M0.00N/AGap UpBPMCBlueprint Medicines2.7806 of 5 stars$95.27+7.4%$124.95+31.2%-6.5%$6.09B$508.82M-88.21640Insider TradePositive NewsKRYSKrystal Biotech4.688 of 5 stars$194.44+3.9%$220.00+13.1%+3.4%$5.60B$290.52M65.03210Positive News Remove Ads Related Companies and Tools Related Companies Sarepta Therapeutics Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Lantheus Competitors TG Therapeutics Competitors Legend Biotech Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Blueprint Medicines Competitors Krystal Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts